Pentazocine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 8: Line 8:
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=Anesthesia; Adjunct: 30 mg IV, IM or SC every 3 to 4 hr as needed, MAX 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended [1]
|fdaLIADAdult=
Labor pain: a single 30 mg/dose IM (most common); OR 20 mg/dose IV for 2-3 doses at 2-3-hr intervals, as needed, after contractions have become regular [1]
* Anesthesia; Adjunct: 30 mg IV, IM or SC every 3 to 4 hr as needed, max 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended.
Pain (Moderate to Severe): 30 mg IV, IM or SC every 3-4 hr as needed, MAX 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended [1]
* Labor pain: a single 30 mg/dose IM (most common); or 20 mg/dose IV for 2-3 doses at 2-3-hr intervals, as needed, after contractions have become regular.
* Pain (moderate to severe): 30 mg IV, IM or SC every 3-4 hr as needed, max 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended.
|offLabelAdultGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Pentazocine in adult patients.
|offLabelAdultGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Pentazocine in adult patients.
|offLabelAdultNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Pentazocine in adult patients.
|offLabelAdultNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Pentazocine in adult patients.
|fdaLIADPed=Safety and effectiveness in children less than 12 yr of age not established
|fdaLIADPed=* Safety and effectiveness in children less than 12 yr of age not established.
Anesthesia; Adjunct: single 0.5 mg/kg IM dose [1]
* Anesthesia; adjunct: single 0.5 mg/kg IM dose
|offLabelPedGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Pentazocine in pediatric patients.
|offLabelPedGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Pentazocine in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Pentazocine in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Pentazocine in pediatric patients.
|contraindications=TALWIN should not be administered to patients who are hypersensitive to it.
|contraindications=
|warnings=Drug Dependence: Special care should be exercised in prescribing pentazocine for emotionally unstable patients and for those with a history of drug misuse. Such patients should be closely supervised when greater than 4 or 5 days of therapy is contemplated. There have been instances of psychological and physical dependence on TALWIN in patients with such a history and, rarely, in patients without such a history. Extended use of parenteral TALWIN may lead to physical or psychological dependence in some patients. When TALWIN is abruptly discontinued, withdrawal symptoms such as abdominal cramps, elevated temperature, rhinorrhea, restlessness, anxiety, and lacrimation may occur. However, even when these have occurred, discontinuance has been accomplished with minimal difficulty. In the rare patient in whom more than minor difficulty has been encountered, reinstitution of parenteral TALWIN with gradual withdrawal has ameliorated the patient’s symptoms. Substituting methadone or other narcotics for TALWIN in the treatment of the pentazocine abstinence syndrome should be avoided. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of TALWIN during pregnancy.
* Pentazocine should not be administered to patients who are hypersensitive to it.
 
|warnings=
In prescribing parenteral TALWIN for chronic use, particularly if the drug is to be self-administered, the physician should take precautions to avoid increases in dose and frequency of injection by the patient.
=====Drug Dependence=====
 
* Special care should be exercised in prescribing pentazocine for emotionally unstable patients and for those with a history of drug misuse. Such patients should be closely supervised when greater than 4 or 5 days of therapy is contemplated. There have been instances of psychological and physical dependence on pentazocine in patients with such a history and, rarely, in patients without such a history. Extended use of parenteral pentazocine may lead to physical or psychological dependence in some patients. When pentazocine is abruptly discontinued, withdrawal symptoms such as abdominal cramps, elevated temperature, rhinorrhea, restlessness, anxiety, and lacrimation may occur. However, even when these have occurred, discontinuance has been accomplished with minimal difficulty. In the rare patient in whom more than minor difficulty has been encountered, reinstitution of parenteral pentazocine with gradual withdrawal has ameliorated the patient’s symptoms. Substituting methadone or other narcotics for pentazocine in the treatment of the pentazocine abstinence syndrome should be avoided. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.
Just as with all medication, the oral form of TALWIN is preferable for chronic administration.
* In prescribing parenteral pentazocine for chronic use, particularly if the drug is to be self-administered, the physician should take precautions to avoid increases in dose and frequency of injection by the patient.
* Just as with all medication, the oral form of pentazocine is preferable for chronic administration.
* Tissue Damage at Injection Sites: Severe sclerosis of the skin, subcutaneous tissues, and underlying muscle have occurred at the injection sites of patients who have received multiple doses of pentazocine lactate. Constant rotation of injection sites is, therefore, essential. In addition, animal studies have demonstrated that pentazocine is tolerated less well subcutaneously than intramuscularly. (See Dosage and Administration.)
=====Head Injury and Increased Intracranial Pressure=====
* As in the case of other potent analgesics, the potential of pentazocine injection for elevating [[cerebrospinal fluid]] pressure may be attributed to CO2 retention due to the respiratory depressant effects of the drug. These effects may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, pentazocine can produce effects which may obscure the clinical course of patients with head injuries. In such patients, pentazocine must be used with extreme caution and only if its use is deemed essential.


Tissue Damage at Injection Sites: Severe sclerosis of the skin, subcutaneous tissues, and underlying muscle have occurred at the injection sites of patients who have received multiple doses of pentazocine lactate. Constant rotation of injection sites is, therefore, essential. In addition, animal studies have demonstrated that TALWIN is tolerated less well subcutaneously than intramuscularly. (See DOSAGE AND ADMINISTRATION.)
=====Acute CNS Manifestations=====
* Patients receiving therapeutic doses of pentazocine have experienced [[hallucinations]] (usually [[visual]]), [[disorientation]], and [[confusion]] which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.
* Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.


Head Injury and Increased Intracranial Pressure: As in the case of other potent analgesics, the potential of TALWIN injection for elevating cerebrospinal fluid pressure may be attributed to CO2 retention due to the respiratory depressant effects of the drug. These effects may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, TALWIN can produce effects which may obscure the clinical course of patients with head injuries. In such patients, TALWIN must be used with extreme caution and only if its use is deemed essential.
=====Ambulatory Patients=====
* Since [[sedation]], [[dizziness]], and occasional [[euphoria]] have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or unnecessarily expose themselves to hazards.


Acute CNS Manifestations: Patients receiving therapeutic doses of pentazocine have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.
=====Myocardial Infarction=====
* Caution should be exercised in the intravenous use of pentazocine for patients with [[acute myocardial infarction]] accompanied by [[hypertension]] or [[left ventricular failure]]. Data suggest that intravenous administration of pentazocine increases systemic and pulmonary arterial pressure and systemic vascular resistance in patients with acute myocardial infarction.


Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
=====NOTE=====
* Acetone sodium bisulfite, a sulfite that may cause allergic-type reactions including [[anaphylactic symptoms]] and life-threatening or less severe asthmatic episodes in certain susceptible people, is contained in multiple-dose vials. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
* The ampuls in the Uni-Amp™ Pak do not contain acetone sodium bisulfite.
|clinicalTrials=
* The most commonly occurring reactions are: [[nausea]], [[dizziness]] or [[lightheadedness]], [[vomiting]], [[euphoria]].


Ambulatory Patients: Since sedation, dizziness, and occasional euphoria have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or unnecessarily expose themselves to hazards.
=====Dermatologic Reactions=====
*  Soft tissue [[induration]], [[nodules]], and cutaneous depression can occur at injection sites. [[Ulceration]] ([[sloughing]]) and severe sclerosis of the skin and subcutaneous tissues (and, rarely, underlying muscle) have been reported after multiple doses. Other reported dermatologic reactions include [[diaphoresis]], sting on injection, flushed skin including [[plethora]], [[dermatitis]] including [[pruritus]].


Myocardial Infarction: Caution should be exercised in the intravenous use of pentazocine for patients with acute myocardial infarction accompanied by hypertension or left ventricular failure. Data suggest that intravenous administration of pentazocine increases systemic and pulmonary arterial pressure and systemic vascular resistance in patients with acute myocardial infarction.
* Infrequently occurring reactions are—respiratory: [[respiratory depression]], [[dyspnea]], transient apnea in a small number of newborn infants whose mothers received pentazocine during labor; [[cardiovascular]]: [[circulatory depression]], [[shock]], [[hypertension]]; CNS effects: [[dizziness]], [[lightheadedness]], [[hallucinations]], [[sedation]], [[euphoria]], [[headache]], [[confusion]], [[disorientation]]; infrequently weakness, [[disturbed dreams]], [[insomnia]], [[syncope]], visual blurring and focusing difficulty, [[depression]]; and rarely [[tremor]], [[irritability]], [[excitement]], [[tinnitus]]; [[gastrointestinal]]: [[constipation]], [[dry mouth]]; other: [[urinary retention]], [[headache]], [[paresthesia]], alterations in rate or strength of uterine contractions during labor.


NOTE: Acetone sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people, is contained in multiple-dose vials. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
* Rarely reported reactions include—[[neuromuscular]] and [[psychiatric]]: [[muscle tremor]], [[insomnia]], [[disorientation]], [[hallucinations]]; [[gastrointestinal]]: taste alteration, [[diarrhea]] and [[cramps]]; [[ophthalmic]]: [[blurred vision]], [[nystagmus]], [[diplopia]], [[miosis]]; [[hematologic]]: depression of [[white blood cells]] (especially [[granulocytes]]), which is usually reversible, moderate transient [[eosinophilia]]; other: tachycardia, weakness or faintness, chills; allergic reactions including edema of the face, [[toxic epidermal necrolysis]]. (See Acute CNS Manifestations and Drug Dependence under Warnings.)
|useInPregnancyFDA=
* Safe use of pentazocine during pregnancy (other than labor) has not been established. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects. However, pentazocine should be administered to pregnant patients (other than labor) only when, in the judgment of the physician, the potential benefits outweigh the possible hazards. Patients receiving pentazocine during labor have experienced no adverse effects other than those that occur with commonly used analgesics. pentazocine should be used with caution in women delivering premature infants.
|useInPed=
* The safety and efficacy of pentazocine as preoperative or preanesthetic medication have been established in pediatric patients 1 to 16 years of age. Use of pentazocine in these age groups is supported by evidence from adequate and controlled studies in adults with additional data from published controlled trials in pediatric patients. The safety and efficacy of pentazocine as a premedication for sedation have not been established in pediatric patients less than one year old. Information on the safety profile of pentazocine as a postoperative analgesic in children less than 16 years is limited.
|useInGeri=
* Elderly patients may be more sensitive to the analgesic effects of pentazocine than younger patients. (See Dosage and Administration.)
* Clinical data indicate that differences in various pharmacokinetic parameters of pentazocine may exist between elderly and younger patients. (See Clinical Pharmacology.)
* Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of pentazocine and observed closely.
* This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
|overdose=
=====Manifestations=====
* Clinical experience with pentazocine overdosage has been insufficient to define the signs of this condition.


The ampuls in the Uni-Amp™ Pak do not contain acetone sodium bisulfite.
=====Treatment=====
|clinicalTrials=The most commonly occurring reactions are: nausea, dizziness or lightheadedness, vomiting, euphoria.
*  Oxygen, [[intravenous fluids]], [[vasopressors]], and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to [[overdosage]] or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist.
 
Dermatologic Reactions: Soft tissue induration, nodules, and cutaneous depression can occur at injection sites. Ulceration (sloughing) and severe sclerosis of the skin and subcutaneous tissues (and, rarely, underlying muscle) have been reported after multiple doses. Other reported dermatologic reactions include diaphoresis, sting on injection, flushed skin including plethora, dermatitis including pruritus.
 
Infrequently occurring reactions are—respiratory: respiratory depression, dyspnea, transient apnea in a small number of newborn infants whose mothers received TALWIN during labor; cardiovascular: circulatory depression, shock, hypertension; CNS effects: dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, disorientation; infrequently weakness, disturbed dreams, insomnia, syncope, visual blurring and focusing difficulty, depression; and rarely tremor, irritability, excitement, tinnitus; gastrointestinal: constipation, dry mouth; other: urinary retention, headache, paresthesia, alterations in rate or strength of uterine contractions during labor.
 
Rarely reported reactions include—neuromuscular and psychiatric: muscle tremor, insomnia, disorientation, hallucinations; gastrointestinal: taste alteration, diarrhea and cramps; ophthalmic: blurred vision, nystagmus, diplopia, miosis; hematologic: depression of white blood cells (especially granulocytes), which is usually reversible, moderate transient eosinophilia; other: tachycardia, weakness or faintness, chills; allergic reactions including edema of the face, toxic epidermal necrolysis. (See Acute CNS Manifestations and Drug Dependence under WARNINGS.)
|useInPregnancyFDA=Safe use of TALWIN during pregnancy (other than labor) has not been established. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects. However, TALWIN should be administered to pregnant patients (other than labor) only when, in the judgment of the physician, the potential benefits outweigh the possible hazards. Patients receiving TALWIN during labor have experienced no adverse effects other than those that occur with commonly used analgesics. TALWIN should be used with caution in women delivering premature infants.
|useInPed=The safety and efficacy of TALWIN as preoperative or preanesthetic medication have been established in pediatric patients 1 to 16 years of age. Use of TALWIN in these age groups is supported by evidence from adequate and controlled studies in adults with additional data from published controlled trials in pediatric patients. The safety and efficacy of TALWIN as a premedication for sedation have not been established in pediatric patients less than one year old. Information on the safety profile of TALWIN as a postoperative analgesic in children less than 16 years is limited.
|useInGeri=Elderly patients may be more sensitive to the analgesic effects of TALWIN than younger patients. (See DOSAGE AND ADMINISTRATION.)
 
Clinical data indicate that differences in various pharmacokinetic parameters of TALWIN may exist between elderly and younger patients. (See CLINICAL PHARMACOLOGY.)
 
Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of TALWIN and observed closely.
 
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
|overdose=Manifestations: Clinical experience with TALWIN overdosage has been insufficient to define the signs of this condition.
 
Treatment: Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdosage or unusual sensitivity to TALWIN, parenteral naloxone is a specific and effective antagonist.
|drugBox={{Drugbox2
|drugBox={{Drugbox2
| Watchedfields = changed
| Watchedfields = changed
| verifiedrevid = 464198314
| verifiedrevid = 464198314
| IUPAC_name = <small>(2''RS'',6''RS'',11''RS'')-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol</small><br />or<br /><small>2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan</small>
| IUPAC_name = <small>(2''RS'',6''RS'',11''RS'')-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol</small><br />or<br /><small>2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan</small>
| image = Pentazocine-racemate2DCSD.svg
| image = Pentazocine wiki1.svg.png
| width = 350px
| width = 350px
| imageL = (R)-pentazocine3DanJ.gif
| imageL = Pentazocine image.gif
| widthL = 175px
| widthL = 175px
| imageR = (S)-pentazocine3DanJ.gif
| imageR = Pentazocine image.gif
| widthR = 175px
| widthR = 175px
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo_Ref = {{cascite|correct|CAS}}
Line 105: Line 114:
| routes_of_administration = Oral, IV, IM
| routes_of_administration = Oral, IV, IM
}}
}}
|structure=TALWIN injection, Pentazocine Injection, USP, is a member of the benzazocine series (also known as the benzomorphan series). Chemically, pentazocine lactate is 1, 2, 3, 4, 5, 6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol lactate, a white, crystalline substance soluble in acidic aqueous solutions.
|structure=
|PD=TALWIN is a potent analgesic and 30 mg is usually as effective an analgesic as morphine 10 mg or meperidine 75 mg to 100 mg; however, a few studies suggest the TALWIN to morphine ratio may range from 20 mg to 40 mg TALWIN to 10 mg morphine. The duration of analgesia may sometimes be less than that of morphine. Analgesia usually occurs within 15 to 20 minutes after intramuscular or subcutaneous injection and within 2 to 3 minutes after intravenous injection. TALWIN weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. TALWIN has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.
* Pentazocine injection, Pentazocine Injection, USP, is a member of the benzazocine series (also known as the benzomorphan series). Chemically, pentazocine lactate is 1, 2, 3, 4, 5, 6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol lactate, a white, crystalline substance soluble in acidic aqueous solutions.
|PK=Clinical data indicate that differences in various pharmacokinetic parameters may be observed with increasing age. In one study, elderly patients exhibited a longer mean elimination half-life, a lower mean total plasma clearance, and a larger mean area under the concentration-time curve than younger patients.
|PD=
* Pentazocine is a potent analgesic and 30 mg is usually as effective an analgesic as morphine 10 mg or meperidine 75 mg to 100 mg; however, a few studies suggest the Pentazocine to morphine ratio may range from 20 mg to 40 mg Pentazocine to 10 mg morphine. The duration of analgesia may sometimes be less than that of morphine. Analgesia usually occurs within 15 to 20 minutes after intramuscular or subcutaneous injection and within 2 to 3 minutes after intravenous injection. Pentazocine weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.
|PK=
* Clinical data indicate that differences in various pharmacokinetic parameters may be observed with increasing age. In one study, elderly patients exhibited a longer mean elimination half-life, a lower mean total plasma clearance, and a larger mean area under the concentration-time curve than younger patients.
|howSupplied=
|howSupplied=
[[File:FILENAME.jpg|thumb|none|400px|left|This image is provided by the National Library of Medicine.]]
[[File:Pentazocinehow supplied.jpg|thumb|none|400px|left|This image is provided by the National Library of Medicine.]]
 
The pH of TALWIN solutions is adjusted between 4 and 5 with lactic acid or sodium hydroxide. The air in the ampuls and vials has been displaced by nitrogen gas.
|storage=Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]


Revised: September, 2010
* The pH of Pentazocine solutions is adjusted between 4 and 5 with lactic acid or sodium hydroxide. The air in the ampuls and vials has been displaced by nitrogen gas.
 
|storage=
* Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
: Revised: September, 2010
: Printed in USA                            EN-2622
: Hospira, Inc., Lake Forest, IL 60045 USA


Printed in USA                            EN-2622


Hospira, Inc., Lake Forest, IL 60045 USA
|alcohol=Alcohol-Pentazocine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=Alcohol-Pentazocine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
}}

Latest revision as of 02:10, 10 June 2014

Pentazocine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Pentazocine is an analgesic opioid that is FDA approved for the {{{indicationType}}} of anesthesia; adjunct, labor pain, pain (moderate to severe). Common adverse reactions include gastrointestinal: nausea, vomiting, neurologic: dizziness, lightheadedness, psychiatric: euphoria.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Anesthesia; Adjunct: 30 mg IV, IM or SC every 3 to 4 hr as needed, max 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended.
  • Labor pain: a single 30 mg/dose IM (most common); or 20 mg/dose IV for 2-3 doses at 2-3-hr intervals, as needed, after contractions have become regular.
  • Pain (moderate to severe): 30 mg IV, IM or SC every 3-4 hr as needed, max 360 mg/day; doses above 30 mg IV or 60 mg IM, SC are not recommended.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Pentazocine in adult patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Pentazocine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Safety and effectiveness in children less than 12 yr of age not established.
  • Anesthesia; adjunct: single 0.5 mg/kg IM dose

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Pentazocine in pediatric patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Pentazocine in pediatric patients.

Contraindications

  • Pentazocine should not be administered to patients who are hypersensitive to it.

Warnings

Drug Dependence
  • Special care should be exercised in prescribing pentazocine for emotionally unstable patients and for those with a history of drug misuse. Such patients should be closely supervised when greater than 4 or 5 days of therapy is contemplated. There have been instances of psychological and physical dependence on pentazocine in patients with such a history and, rarely, in patients without such a history. Extended use of parenteral pentazocine may lead to physical or psychological dependence in some patients. When pentazocine is abruptly discontinued, withdrawal symptoms such as abdominal cramps, elevated temperature, rhinorrhea, restlessness, anxiety, and lacrimation may occur. However, even when these have occurred, discontinuance has been accomplished with minimal difficulty. In the rare patient in whom more than minor difficulty has been encountered, reinstitution of parenteral pentazocine with gradual withdrawal has ameliorated the patient’s symptoms. Substituting methadone or other narcotics for pentazocine in the treatment of the pentazocine abstinence syndrome should be avoided. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.
  • In prescribing parenteral pentazocine for chronic use, particularly if the drug is to be self-administered, the physician should take precautions to avoid increases in dose and frequency of injection by the patient.
  • Just as with all medication, the oral form of pentazocine is preferable for chronic administration.
  • Tissue Damage at Injection Sites: Severe sclerosis of the skin, subcutaneous tissues, and underlying muscle have occurred at the injection sites of patients who have received multiple doses of pentazocine lactate. Constant rotation of injection sites is, therefore, essential. In addition, animal studies have demonstrated that pentazocine is tolerated less well subcutaneously than intramuscularly. (See Dosage and Administration.)
Head Injury and Increased Intracranial Pressure
  • As in the case of other potent analgesics, the potential of pentazocine injection for elevating cerebrospinal fluid pressure may be attributed to CO2 retention due to the respiratory depressant effects of the drug. These effects may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, pentazocine can produce effects which may obscure the clinical course of patients with head injuries. In such patients, pentazocine must be used with extreme caution and only if its use is deemed essential.
Acute CNS Manifestations
  • Patients receiving therapeutic doses of pentazocine have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.
  • Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
Ambulatory Patients
  • Since sedation, dizziness, and occasional euphoria have been noted, ambulatory patients should be warned not to operate machinery, drive cars, or unnecessarily expose themselves to hazards.
Myocardial Infarction
  • Caution should be exercised in the intravenous use of pentazocine for patients with acute myocardial infarction accompanied by hypertension or left ventricular failure. Data suggest that intravenous administration of pentazocine increases systemic and pulmonary arterial pressure and systemic vascular resistance in patients with acute myocardial infarction.
NOTE
  • Acetone sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people, is contained in multiple-dose vials. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
  • The ampuls in the Uni-Amp™ Pak do not contain acetone sodium bisulfite.

Adverse Reactions

Clinical Trials Experience

Dermatologic Reactions
  • Soft tissue induration, nodules, and cutaneous depression can occur at injection sites. Ulceration (sloughing) and severe sclerosis of the skin and subcutaneous tissues (and, rarely, underlying muscle) have been reported after multiple doses. Other reported dermatologic reactions include diaphoresis, sting on injection, flushed skin including plethora, dermatitis including pruritus.

Postmarketing Experience

There is limited information regarding Pentazocine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Pentazocine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Safe use of pentazocine during pregnancy (other than labor) has not been established. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects. However, pentazocine should be administered to pregnant patients (other than labor) only when, in the judgment of the physician, the potential benefits outweigh the possible hazards. Patients receiving pentazocine during labor have experienced no adverse effects other than those that occur with commonly used analgesics. pentazocine should be used with caution in women delivering premature infants.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pentazocine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pentazocine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pentazocine in women who are nursing.

Pediatric Use

  • The safety and efficacy of pentazocine as preoperative or preanesthetic medication have been established in pediatric patients 1 to 16 years of age. Use of pentazocine in these age groups is supported by evidence from adequate and controlled studies in adults with additional data from published controlled trials in pediatric patients. The safety and efficacy of pentazocine as a premedication for sedation have not been established in pediatric patients less than one year old. Information on the safety profile of pentazocine as a postoperative analgesic in children less than 16 years is limited.

Geriatic Use

  • Elderly patients may be more sensitive to the analgesic effects of pentazocine than younger patients. (See Dosage and Administration.)
  • Clinical data indicate that differences in various pharmacokinetic parameters of pentazocine may exist between elderly and younger patients. (See Clinical Pharmacology.)
  • Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of pentazocine and observed closely.
  • This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

There is no FDA guidance on the use of Pentazocine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pentazocine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pentazocine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pentazocine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pentazocine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pentazocine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Pentazocine Administration in the drug label.

Monitoring

There is limited information regarding Pentazocine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Pentazocine and IV administrations.

Overdosage

Manifestations
  • Clinical experience with pentazocine overdosage has been insufficient to define the signs of this condition.
Treatment
  • Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist.

Pharmacology

Template:Px
Pentazocine
Systematic (IUPAC) name
(2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
or
2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan
Identifiers
CAS number 359-83-1
ATC code N02AD01
PubChem 441278
DrugBank DB00652
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 285.424 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ~20% orally
Metabolism Hepatic
Half life 2 to 3 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C(AU) ?(US)

Legal status

Controlled (S8)(AU) Schedule IV(US) Schedule III (international)

Routes Oral, IV, IM

Mechanism of Action

There is limited information regarding Pentazocine Mechanism of Action in the drug label.

Structure

  • Pentazocine injection, Pentazocine Injection, USP, is a member of the benzazocine series (also known as the benzomorphan series). Chemically, pentazocine lactate is 1, 2, 3, 4, 5, 6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol lactate, a white, crystalline substance soluble in acidic aqueous solutions.

Pharmacodynamics

  • Pentazocine is a potent analgesic and 30 mg is usually as effective an analgesic as morphine 10 mg or meperidine 75 mg to 100 mg; however, a few studies suggest the Pentazocine to morphine ratio may range from 20 mg to 40 mg Pentazocine to 10 mg morphine. The duration of analgesia may sometimes be less than that of morphine. Analgesia usually occurs within 15 to 20 minutes after intramuscular or subcutaneous injection and within 2 to 3 minutes after intravenous injection. Pentazocine weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.

Pharmacokinetics

  • Clinical data indicate that differences in various pharmacokinetic parameters may be observed with increasing age. In one study, elderly patients exhibited a longer mean elimination half-life, a lower mean total plasma clearance, and a larger mean area under the concentration-time curve than younger patients.

Nonclinical Toxicology

There is limited information regarding Pentazocine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Pentazocine Clinical Studies in the drug label.

How Supplied

This image is provided by the National Library of Medicine.
  • The pH of Pentazocine solutions is adjusted between 4 and 5 with lactic acid or sodium hydroxide. The air in the ampuls and vials has been displaced by nitrogen gas.

Storage

  • Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Revised: September, 2010
Printed in USA EN-2622
Hospira, Inc., Lake Forest, IL 60045 USA

Images

Drug Images

{{#ask: Page Name::Pentazocine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pentazocine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Pentazocine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Pentazocine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Pentazocine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Pentazocine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject: 

 |Label Page=Pentazocine
 |Label Name=Pentazocine label.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Pentazocine&oldid=976937"